Filing Analysis
DataMeds AI, Inc. issued an 8-K to announce its financial results for the second quarter ended June 30, 2026, and provided a general business update via a press release.
📋 Key Facts
- Reporting period: Second quarter ended June 30, 2026.
- Announcement date: August 17, 2026.
- The filing includes a press release (Exhibit 99.1) containing financial results and a business update.
- The company is an emerging growth company.
DataMeds AI, Inc. announced a voluntary one-time distribution of 'Dream Bowl 2026 Meme Coin' tokens to shareholders of record as of August 7, 2026. The distribution is facilitated through a licensing partner, Datavault AI Inc., and requires shareholders to set up a digital wallet and execute an opt-in agreement.
🚩 Red Flags
- High volatility/speculative nature of the distributed asset (meme coin).
- Complexity of receipt: Requires shareholders to manage digital wallets and execute legal opt-in agreements.
- Potential regulatory risk regarding 'tokenized assets' as noted in the company's own cautionary language.
📋 Key Facts
- Distribution rate: 50 Dream Bowl 2026 Meme Coins for every 1 share of DataMeds Common Stock held on the record date.
- Record Date: August 7, 2026 (subject to change by Datavault's board).
- Payment Date: Scheduled to begin September 9, 2026 (subject to satisfaction of payment conditions).
- Requirements for receipt: Shareholders must set up a digital wallet with Datavault and execute an 'Opt-In Agreement'.
- The distribution is being made by licensing partner Datavault AI Inc., not directly by DataMeds AI, Inc.
DataMeds AI, Inc. entered into an Amended and Restated Letter of Intent to acquire intellectual property assets from EOS Technology Holdings and Scilex Holding Company, expand a pharmacy license with Datavault AI, and acquire a controlling interest in Tollo Health, LLC via a massive equity exchange.
🚩 Red Flags
- Extreme dilution: Existing public stockholders are expected to be diluted down to approximately 10.4% ownership.
- Potential Change in Control: The transaction structure likely triggers Nasdaq Listing Rule 5110(a), requiring initial listing application approval.
- Uncertainty regarding liabilities: The LOI mentions 'liability reduction or financing transactions' required to address outstanding Company liabilities prior to closing.
- Significant dilution risk from registration rights: The company must file an S-3/S-1 within 45 days of closing for the resale of Acquisition Stock.
📋 Key Facts
- The transaction involves an issuance of common stock (Acquisition Stock) to EOS, Scilex, Datavault, and HBA.
- Post-closing ownership structure: EOS (19.9%), Scilex (19.9%), Datavault (19.9%), HBA (24.9%), Fortitude (5%), and existing public stockholders (~10.4%).
- The deal includes the acquisition of 'Quality of Life Peace of Mind' (QOLPOM / QLPM) related IP assets.
- The Company will acquire a controlling interest in Tollo Health, LLC through an exchange of membership interests with HBA.
- Post-closing management changes include two new management team members and four board designees.
- The LOI includes a 6-month lock-up period for certain holders of Acquisition Stock.
DataMeds AI, Inc. announced an update to the record date for the distribution of its 'Dream Bowl 2026 Meme Coin'. The new record date is set for August 7, 2026.
🚩 Red Flags
- Involvement in 'Meme Coin' distribution may indicate high volatility and speculative business activities typical of micro-cap companies.
📋 Key Facts
- The company updated the record date for the Dream Bowl 2026 Meme Coin distribution to August 7, 2026.
- The announcement was made via a press release on July 27, 2026.
- The registrant is an emerging growth company.
Wellgistics Health, Inc. is changing its corporate name to 'DataMeds AI, Inc.' and updating its Nasdaq trading symbol from 'WGRX' to 'MEDS', effective July 22, 2026.
🚩 Red Flags
- Name change to include 'AI' often signals a pivot or rebranding attempt common in micro-cap companies seeking to capitalize on current market trends, though this is not inherently negative without further context.
📋 Key Facts
- New Company Name: DataMeds AI, Inc.
- New Trading Symbol: MEDS
- Effective Date of Change: July 22, 2026
- The change was filed via a Certificate of Amendment to the Amended and Restated Certificate of Incorporation in Delaware.
- No stockholder approval was required for this name change under Section 242 of the General Corporation Law of Delaware.
- CUSIP number remains unchanged: 949503205.
Wellgistics Health received an extension from Nasdaq to remedy a deficiency in stockholders' equity, which was negative $(12,447,801) as of December 31, 2025. While the company has regained compliance with the minimum bid price requirement, it must now prove it meets the $2.5 million equity threshold by October 12, 2026.
🚩 Red Flags
- Severe negative stockholders' equity of over $12 million for a micro-cap company.
- Dependence on speculative future transactions (merger and acquisitions) to avoid delisting.
- Multiple 8-K items (3.01 and 8.01) indicating ongoing volatility in listing status.
📋 Key Facts
- Stockholders' equity as of December 31, 2025, was negative $(12,447,801), failing Nasdaq Rule 5550(b)(1) which requires at least $2,500,000.
- Nasdaq granted an extension until October 12, 2026, to regain compliance with the equity requirement.
- The company plans to remedy the deficiency through a combination with DataVault AI (creating 'DelivMeds AI') and the acquisition of a patent portfolio and stake in Tollo Health.
- Management estimates post-transaction stockholders' equity of approximately $40 million and combined asset value of $4 billion.
- The company successfully regained compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) as of June 9, 2026.
Wellgistics Health, Inc. filed Amendment No. 2 to a previous 8-K to replace and refile Exhibit 4.3, which is the Form of Placement Agent Warrant. This is a technical correction to a prior filing and does not report new material events.
📋 Key Facts
- The filing is an Amendment No. 2 to a Current Report on Form 8-K originally filed on May 29, 2026.
- The primary purpose is to replace and refile Exhibit 4.3 (Form of Placement Agent Warrant).
- The filing date is June 3, 2026, regarding events that occurred on May 27, 2026.
Wellgistics Health, Inc. filed an 8-K/A amendment to provide exhibits that were omitted from a previous filing. The omitted documents include a Form of Placement Agent Warrant and a press release dated May 27, 2026, indicating a recent securities offering.
🚩 Red Flags
- Administrative oversight: The company inadvertently omitted material exhibits (Warrants and Press Release) from its original 8-K filing, suggesting poor internal controls over SEC reporting.
📋 Key Facts
- The filing is an Amendment No. 1 to a Current Report on Form 8-K originally filed on May 29, 2026.
- The amendment was filed on June 2, 2026.
- The primary purpose was to include Exhibit 4.3 (Form of Placement Agent Warrant) and Exhibit 99.1 (Press Release from May 27, 2026).
- The company is registered on the Nasdaq Capital Market under the ticker WGRX.
Wellgistics Health, Inc. entered into a Securities Purchase Agreement on May 27, 2026, to issue convertible promissory notes with an aggregate principal amount of $21,132,812.50. The offering includes a significant original issue discount (OID) and warrants, with proceeds partially used to repay a $1.77 million debt to Marco Capital, Inc.
🚩 Red Flags
- Significant 20% Original Issue Discount (OID) indicates high cost of capital and potential desperation for liquidity
- Complex 'death spiral' characteristics: conversion price is tied to 100% of the closing price, allowing for significant dilution if the stock price drops
- Liquidated damages provision in the Registration Rights Agreement (1.5% of subscription amount) creates a financial penalty for SEC delays
- The use of proceeds to pay off existing debt (Marco Capital) rather than purely for growth/working capital
📋 Key Facts
- Aggregate principal amount of Notes: $21,132,812.50
- Aggregate cash proceeds received: $16,906,250 (reflecting a 20% original issue discount)
- Notes mature in 12 months and bear 0% interest
- Notes are convertible into Common Stock at the lesser of $6.00 or 100% of the prior day's closing price (floor of $1.00)
- Automatic conversion into Series A Convertible Preferred Stock occurs upon the 'Mandatory Conversion Date'
- Series A Preferred Stock accrues 10% dividends after six months
- PIPE Warrants exercise price: $7.50; Placement Agent Warrants exercise price: $6.25
- Used proceeds to repay approximately $1.77 million in obligations to Marco Capital, Inc.
Wellgistics Health, Inc. issued a letter to its shareholders on May 21, 2026, providing a strategy overview and business update.
📋 Key Facts
- The filing was made under Item 8.01 (Other Events) on May 21, 2026.
- The company attached a Letter to Shareholders as Exhibit 99.1.
- The letter outlines the company's current strategy overview and business update.
Wellgistics Health, Inc. (WGRX) filed a multi-item 8-K disclosing a 1-for-50 reverse stock split effective May 26, 2026 to regain Nasdaq compliance, alongside a Fully Binding Letter of Intent for a transformative multi-party acquisition that would result in existing public shareholders retaining only ~10.4% of the combined company. The filing also discloses an amendment to a promissory note with a 20% OID, appointment of an Interim Co-CEO with significant related-party ties, and a proposed corporate rename to DelivMeds AI, Inc.
🚩 Red Flags
- 1-for-50 reverse stock split is an extreme ratio, signaling severe share price deterioration and Nasdaq non-compliance (Rule 5550(a)(2) bid price deficiency)
- Existing public shareholders face ~89.6% dilution upon conversion of Acquisition Preferred — near-total economic displacement
- Newly appointed Interim Co-CEO (Commissiong) has direct financial interest in the transaction through Fortitude Advisors (~5.0% of post-conversion common stock) and is CEO of an acquisition target (Tollo Health) — severe related-party conflict
- Promissory note carries a 20% original issue discount, indicating predatory/distressed financing terms; aggregate OID burden = $300,000 on $1.5M principal
- Six separate 8-K items filed simultaneously, indicating multiple concurrent material events under financial and operational stress
- Company explicitly states it 'cannot provide assurance' the reverse split will achieve desired effects or maintain Nasdaq listing
- $4.0 billion combined valuation claim is highly speculative for a micro-cap with no definitive agreements, no completed due diligence, and no fairness opinion yet issued
- Binding exclusivity provisions lock the company into negotiations, limiting strategic alternatives during a vulnerable period
- Corporate name change to DelivMeds AI, Inc. suggests pivot away from core pharmacy/health operations — strategic direction uncertainty
📋 Key Facts
- 1-for-50 reverse stock split approved by board (April 2, 2026) and majority stockholders; effective 12:01 a.m. ET on May 26, 2026 under existing symbol WGRX
- Reverse split explicitly triggered by Nasdaq non-compliance with Listing Rule 5550(a)(2) — bid price below $1.00
- Binding LOI dated May 20, 2026 with EOS Technology Holdings, Scilex Holding Company (SCLX), Datavault AI, HealthBridge Advisors, and Fortitude Advisors for multi-party asset acquisition
- Transaction would issue 'Acquisition Preferred' convertible into ~89.6% of common stock to transaction counterparties; existing public shareholders retain only ~10.4%
- Proposed combined entity valuation of $4.0 billion per term sheet, subject to fairness opinion
- Amendment No. 1 to Note Purchase Agreement with Robert Forster (May 19, 2026): additional $200,000 funded, aggregate cash raised to $1,200,000, note principal increased to $1,500,000 with 20% original issue discount
- Gerald Commissiong appointed Interim Co-CEO effective May 20, 2026; he is simultaneously Managing Partner of Fortitude Advisors (a Term Sheet counterparty expected to receive ~5.0% of common stock) and CEO of Tollo Health (target acquisition)
- Term Sheet contemplates corporate name change to DelivMeds AI, Inc., two new management members, and four new board designees
- At-the-market funding facility filing required within 14 days of Term Sheet; target concurrent minimum investment of $2.0 million from Dawson James-associated investors
- No assurance provided that Nasdaq listing will be maintained or that the proposed transaction will be consummated
Wellgistics Health, Inc. filed a Form 8-K on May 19, 2026, to announce its financial results for the quarter ended March 31, 2026. The filing incorporates Item 2.02 and Item 7.01, referencing an attached press release.
📋 Key Facts
- Wellgistics Health, Inc. reported its financial results for the quarter ended March 31, 2026.
- The press release was furnished as Exhibit 99.1 under Items 2.02 and 7.01.
- The filing was signed by CEO Prashant Patel on May 19, 2026.
Wellgistics Health, Inc. announced that it will report its first quarter 2026 financial results on Tuesday, May 19, 2026, after the market closes.
📋 Key Facts
- Wellgistics Health announced on May 15, 2026, that it will release its Q1 2026 financial results on May 19, 2026, after market close.
- The announcement was made via a press release furnished as Exhibit 99.1.
- The filing was submitted under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits).
Wellgistics Health, Inc. has withdrawn its Preliminary Proxy Statement filed on May 14, 2026, regarding a special meeting of stockholders. The company stated the withdrawal is necessary as they continue to evaluate potential strategic transactions.
🚩 Red Flags
- Abrupt withdrawal of proxy materials shortly after filing suggests internal indecision or a sudden change in corporate direction.
- Lack of specificity regarding the 'strategic transactions' creates uncertainty for investors.
📋 Key Facts
- The withdrawal request was filed on May 18, 2026, only four days after the initial proxy filing.
- The proxy materials related to a special meeting of stockholders.
- No definitive proxy materials were distributed or mailed to stockholders prior to the withdrawal.
- The company cited the evaluation of 'potential strategic transactions' as the primary reason for the pivot.
- Revised proxy materials may be filed at a later date depending on the outcome of strategic evaluations.
Wellgistics Health, Inc. entered into a forbearance agreement with Marco Capital, Inc. regarding approximately $1.77 million in outstanding debt. The agreement requires bi-weekly payments and imposes a high interest rate while providing only a short-term reprieve through June 15, 2026.
🚩 Red Flags
- Existence of a forbearance agreement indicates a prior default or inability to meet original loan terms.
- Very high interest rate (SOFR + 11.5%) typical of distressed debt.
- Short forbearance window (approx. 6 weeks) suggests immediate liquidity crisis.
- Personal guaranties from management (Prashant Patel and Eric Sherb) increase risk profile.
- Mandatory sweep of future financing proceeds limits the company's ability to use new capital for operations.
📋 Key Facts
- Acknowledged $1.77 million in outstanding debt under a November 2024 Loan and Security Agreement.
- Forbearance period is extremely short, expiring on June 15, 2026.
- Interest rate set at Term SOFR plus 11.5% per annum starting May 5, 2026.
- Required bi-weekly payments of $50,000 beginning May 5, 2026.
- Net proceeds from future financing transactions must be partially applied to the debt repayment.
- Management members Prashant Patel and Eric Sherb reaffirmed personal guaranties.
Wellgistics Health, Inc. filed an amendment (8-K/A) to a previous report to correct the reporting date to February 9, 2026, and to restate the entry into an Amended Settlement Agreement with Silverback Capital Corporation.
🚩 Red Flags
- The company is filing an amendment to correct the date and restate a material agreement, which may indicate poor internal controls over financial reporting or filing accuracy.
📋 Key Facts
- The filing is an Amendment No. 1 to a Current Report originally filed on February 13, 2026.
- The report corrects the Date of Report to February 9, 2026.
- The company entered into an Amended Settlement Agreement with Silverback Capital Corporation on February 9, 2026.
- The filing specifically restates Item 1.01 to clarify the timing and nature of the material definitive agreement.
Wellgistics Health filed an amended 8-K disclosing a Nasdaq delisting notice due to failure to meet the minimum stockholders' equity requirement of $2.5 million. Simultaneously, the company entered into a collaboration agreement to form a joint venture (Healthstar) with Kare Rx Hub and others, paying up to $2 million in common stock for assets.
🚩 Red Flags
- Severe negative stockholders' equity of approximately -$12.45 million.
- Delisting notice from Nasdaq Capital Market.
- Multiple 8-K items in a single filing (1.01, 3.01, 3.02, 7.01), indicating high volatility/activity.
- Issuance of unregistered shares to resolve asset acquisition while facing insolvency/delisting risks.
📋 Key Facts
- Received Nasdaq Notification Letter on April 13, 2026, regarding non-compliance with Listing Rule 5550(b)(1).
- Company's stockholders' equity was reported as $(12,447,801) as of December 31, 2025, far below the $2.5 million requirement.
- Deadline to submit a compliance plan to Nasdaq is May 28, 2026.
- Entered into a Collaboration Agreement on April 13, 2026, to form 'Healthstar' (51% owned by Wellgistics, 49% by Kare Hub).
- Agreed to pay Kare Pharmtech $2,000,000 in unregistered common stock for transferred assets.
- Initial issuance of 1,500,000 shares at closing, with potential additional shares by April 1, 2027, to reach the $2M valuation.
Wellgistics Health (WGRX) entered into a Collaboration Agreement with Kare Rx Hub to form a joint venture, Healthstar Technologies, LLC, in which WGRX will hold a 51% interest. The company will acquire intellectual property assets for $2 million, payable in common stock, with a share reconciliation provision scheduled for April 2027.
🚩 Red Flags
- Potential for significant future dilution due to the price-based share reconciliation clause on April 1, 2027, which acts as a floorless reset.
- Discrepancy in dates: Agreement signed April 13, 2026, but closing mentioned as occurring on or about April 10, 2026.
📋 Key Facts
- WGRX acquires 51% membership interest in newly formed Healthstar Technologies, LLC.
- Total consideration is $2,000,000 in unregistered common stock.
- Initial issuance of 1,500,000 shares at closing.
- A 'Reconciliation Date' of April 1, 2027, allows for additional share issuance to ensure the $2M value is met based on a 2-day VWAP.
- Shares are subject to a 12-month lock-up period.
Wellgistics Health, Inc. terminated a Settlement Agreement with Silverback Capital Inc. that facilitated debt-for-equity swaps under Section 3(a)(10). The company issued 6,866,000 shares prior to termination and is ending the arrangement to prevent further dilution and pursue alternative financing.
🚩 Red Flags
- Reliance on Section 3(a)(10) share issuances, which are often highly dilutive and used by companies in financial distress.
- Significant share issuance (6.86M shares) occurred in a very short window (approximately 2 months).
- Sudden termination of a material financing structure suggests a shift in strategy or potential friction with the settlement terms.
📋 Key Facts
- Termination notice delivered to Silverback Capital Inc. on April 3, 2026.
- The original Settlement Agreement and Stipulation was dated January 28, 2026.
- A total of 6,866,000 shares of common stock were issued under the agreement prior to its termination.
- The agreement utilized Section 3(a)(10) of the Securities Act of 1933 for share issuance.
- Silverback Capital Inc. has been requested to return all rights and interests in unpaid claims to the original creditors.
Wellgistics Health, Inc. entered into a Note Purchase Agreement to raise $1,000,000 in cash through the issuance of $1,250,000 in promissory notes, representing a 20% original issue discount. The notes mature in 12 months or upon the closing of a qualified financing and carry restrictive covenants against additional debt.
🚩 Red Flags
- High cost of capital: 20% original issue discount for a 12-month term.
- Restrictive covenants: The company cannot incur additional debt or liens, which may severely limit operational flexibility if cash needs exceed the $1M raised.
- Potential for dilution: Investors have participation rights in future offerings for up to 100% of their principal.
📋 Key Facts
- Note Purchase Agreement dated April 1, 2026, for up to $1,250,000 in aggregate principal.
- Investors paid an aggregate purchase price of $1,000,000, reflecting a 20% original issue discount (OID).
- Notes carry a 0% interest rate, increasing to 15% only in the event of default.
- Maturity is set for the 12-month anniversary of issuance or the closing of the next 'Qualified Financing'.
- Investors receive a right to participate in future offerings up to 100% of their note principal for at least one year.
- The company is prohibited from incurring new debt or granting liens while the notes are outstanding.
Wellgistics Health, Inc. entered into a 36-month Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC to distribute the 'KARE Verify' benefits verification product. The agreement provides for a 50/50 net revenue split between the two companies.
📋 Key Facts
- Agreement signed on March 6, 2026, with Kare PharmTech LLC.
- Product involved is 'KARE Verify,' which provides benefits and eligibility verification services.
- Wellgistics will utilize its pharmacy, manufacturer, and distribution channels, including telemedicine platforms, for marketing.
- Net revenue will be shared equally (50% each) between the Company and PharmTech.
- The agreement has a standard term of 36 months unless terminated earlier.
Wellgistics Health, Inc. issued a press release on March 9, 2026, regarding the company's projects, potential financial performance, and growth opportunities. The information was furnished under Item 7.01 and is not considered filed for regulatory liability purposes.
📋 Key Facts
- Press release issued and furnished on March 9, 2026
- Company is classified as an emerging growth company
- Common stock is listed on The Nasdaq Capital Market under the symbol WGRX
- Reference made to a Registration Statement on Form S-1 that became effective on September 25, 2025
Wellgistics Health, Inc. has obtained court approval for a settlement agreement with Silverback Capital Corporation to settle liabilities exceeding $10.7 million through the issuance of common stock. The settlement includes significant dilution via share tranches priced as low as $0.25 per share and additional shares for settlement and legal fees.
🚩 Red Flags
- Massive potential dilution: Issuing stock to settle $10.7M in debt at prices as low as $0.25 per share will significantly dilute existing shareholders.
- Debt-for-equity swap: The company is using equity to settle 'bona fide liabilities,' suggesting liquidity constraints.
- Related party transaction: Appointment of Gerald Commissiong (via Fortitude Advisors, LLC) as consulting CBO.
- Low-price tranches: Fixed price of $0.25 for the first tranche indicates highly favorable terms for the creditor over common shareholders.
📋 Key Facts
- Court approved a Settlement Agreement with Silverback Capital Corporation (SCC) on February 4, 2026.
- Settlement covers liabilities/obligations totaling at least $10,712,734.16.
- Shares will be issued in tranches at prices ranging from $0.25 to $2.25 per share.
- An amendment fixed the first $2,250,000 tranche price at a low of $0.25 per share.
- Company to issue 100,000 shares as a settlement fee and 300,000 shares for legal fees/expenses.
- Gerald Commissiong appointed as consulting Chief Business Officer via Fortitude Advisors, LLC.
Wellgistics Health, Inc. announced the election of Gary Herman to its Board of Directors, effective February 4, 2026. Mr. Herman will serve as an independent director and has been appointed Chairman of the Audit Committee.
📋 Key Facts
- Gary Herman elected to the Board of Directors effective February 4, 2026.
- Mr. Herman appointed as Chairman of the Audit Committee; designated as an 'independent' director.
- Non-employee directors receive a $120,000 annual cash retainer (payable quarterly) or equivalent in stock.
- Non-employee directors receive 60,000 shares annually under the 2023 Equity Incentive Plan.
- New appointment includes 200,000 restricted shares vesting over three years.
Wellgistics Health, Inc. announced the immediate resignation of two key board members on February 1, 2026: Steven Lee and Howard Doss. Notably, Mr. Doss served as the Chairman of the Audit Committee.
🚩 Red Flags
- Simultaneous departure of two board members is unusual for a micro-cap company.
- Loss of the Audit Committee Chairman (Howard Doss) creates immediate governance and oversight risk.
- Immediate effectiveness of resignations can sometimes signal internal friction, despite the 'no disagreement' disclaimer.
📋 Key Facts
- Steven Lee resigned from the Board of Directors effective February 1, 2026; he was a member of the Ethics Committee.
- Howard Doss resigned from the Board of Directors effective February 1, 2026; he served as Chairman of the Audit Committee.
- Both directors stated their resignations were not due to any disagreements with the Company regarding operations, policies, or practices.
Wellgistics Health, Inc. entered into a note purchase agreement to issue up to $8.125 million in secured convertible promissory notes with a 20% original issue discount. The debt is due within six months or upon the next qualified financing and is secured by company assets and intellectual property.
🚩 Red Flags
- High-cost financing: The 20% original issue discount represents significant dilution for existing shareholders.
- Short maturity/Liquidity pressure: Debt is due in only six months or upon the next financing, creating a 'ticking clock' scenario.
- Restrictive covenants: Company is prohibited from incurring new debt or liens (except on IP) while notes are outstanding.
- Secured status: The notes are secured by company assets and intellectual property, increasing creditor priority over common shareholders.
📋 Key Facts
- Aggregate principal amount of Notes: Up to $8,125,000.
- Total purchase price (net proceeds): $6,500,000 due to a 20% original issue discount.
- Conversion Price: Fixed at $0.4057 per share.
- Maturity Date: Six months from issuance or upon the next 'Qualified Financing'.
- Interest Rate: 0% (standard); 18% per annum in the event of default.
- Security: Secured by company assets and a specific Intellectual Property Security Agreement.
- Placement Agent: Dawson James Securities, Inc. received a 6.5% commission and warrants equal to 5% of gross proceeds.
Wellgistics Health, Inc. entered into a note purchase agreement to issue up to $3.125 million in convertible promissory notes with a 20% original issue discount. The financing is structured as a bridge to a future qualified financing of at least $2 million.
🚩 Red Flags
- High-cost financing: The 20% original issue discount represents significant dilution for existing shareholders.
- Short maturity/Liquidity pressure: The notes are due in only 6 months or upon a successful $2M capital raise, creating immediate liquidity risk if the company cannot secure further funding.
- Restrictive covenants: The company is prohibited from incurring new debt or encumbering assets (except IP) while notes are outstanding.
- Potential for massive dilution: Conversion at a floor price of $0.08 in a micro-cap context often leads to significant downward pressure on share price.
📋 Key Facts
- Aggregate principal amount of Notes: Up to $3,125,000.
- Total proceeds to Company: $2,500,000 (reflecting a 20% original issue discount).
- Maturity date: 6 months from issuance or upon a 'Qualified Financing' of at least $2,000,000.
- Interest rate: 0%, increasing to 18% per annum in the event of default.
- Conversion feature: Notes are convertible into equity securities issued in a future Qualified Financing, with a floor price of $0.08 per share.
- Placement Agent: Dawson James Securities, Inc. received 6.5% commission ($162,500) and warrants equal to 5% of gross proceeds.
Wellgistics Health, Inc. filed an 8-K to furnish a press release containing forward-looking statements regarding the company's projects and growth opportunities. The filing does not contain specific material financial or corporate changes but serves as a vehicle for Regulation FD disclosure.
📋 Key Facts
- The company issued a press release on December 17, 2025 (Exhibit 99.1).
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure) and Item 9.01.
- The registrant is an emerging growth company.
- The press release contains forward-looking statements regarding potential financial performance and growth opportunities.
Wellgistics Health, Inc. received a notice from Nasdaq stating it is in violation of the Bid Price Rule after failing to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. The company has been granted an initial 180-day compliance period ending June 8, 2026.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to regain compliance
- Failure to maintain minimum bid price indicates significant downward pressure on share price
📋 Key Facts
- Received Nasdaq notice on December 10, 2025.
- Violation: Failure to maintain a minimum closing bid price of $1.00 per share (Nasdaq Listing Rule 5550(a)(2)).
- Compliance period expires June 8, 2026.
- The company may be eligible for an additional 180-day extension if it meets other Nasdaq requirements and provides notice of intent to cure via a reverse stock split.
Wellgistics Health, Inc. filed an 8-K to furnish a press release containing forward-looking statements regarding the company's projects and growth opportunities under Item 7.01.
📋 Key Facts
- The filing was made on December 8, 2025.
- The company is an emerging growth company.
- A press release dated December 8, 2025, was furnished as Exhibit 99.1.
- The report includes forward-looking statements regarding potential financial performance and growth opportunities.
Wellgistics Health, Inc. filed an 8-K to furnish a press release containing forward-looking statements regarding the company's projects and growth opportunities under Item 7.01.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- A press release was issued on December 4, 2025, which is furnished as Exhibit 99.1.
- The company identifies itself as an emerging growth company.
- The filing contains standard forward-looking statement disclaimers.
Wellgistics Health, Inc. entered into a significant license agreement with DataVault AI Inc. to utilize intellectual property for its 'PharmacyChain™' blockchain technology. The agreement involves substantial upfront and ongoing royalty obligations.
🚩 Red Flags
- Significant cash outflow requirement: $2.5M non-refundable fee due within ~5 weeks of the report date.
- Extremely high royalty burden: 13% of net profit and a massive 90% revenue share on sublicenses is highly dilutive to company margins.
- High minimum annual commitment ($1M) starting in 2028 creates significant long-term fixed cost pressure.
📋 Key Facts
- Entered into License Agreement with DataVault AI Inc. on November 24, 2025.
- Purpose: Development of manufacturer-to-patient blockchain-enabled smart contracts (PharmacyChain™).
- Upfront Fee: $2,500,000 non-refundable license fee due by December 31, 2025.
- Royalty Rate: 13% on all net profit derived from the use of the license.
- Minimum Royalty: $1,000,000 annual minimum starting in calendar year 2028 (subject to a $2M net profit threshold for 2028 and 2029).
- Sublicensing Terms: Company must remit 90% of all net revenue from sublicenses to DataVault AI Inc.
Wellgistics Health, Inc. entered into a sponsorship agreement with Cutting Edge Sports Management, LLC (CESM) for branding and broadcasting opportunities at the Dream Bowl XIV event.
🚩 Red Flags
- Short duration of agreement (approx. 2.5 months) relative to the $250k outlay may suggest high burn rate for short-term marketing exposure.
📋 Key Facts
- Agreement date: November 26, 2025
- Counterparty: Cutting Edge Sports Management, LLC (CESM)
- Sponsorship fee: $250,000.00
- Event: Dream Bowl XIV in Arlington, TX (January 8-11, 2026)
- Agreement term: Execution date to February 15, 2026
- Benefits include broadcasting, branding opportunities, and access to CESM intellectual property
Wellgistics Health, Inc. entered into a significant license agreement with DataVault AI Inc. to utilize intellectual property for its 'PharmacyChain™' blockchain technology. The deal involves substantial upfront and ongoing payments that could heavily impact the company's cash flow and profit margins.
🚩 Red Flags
- High cash outflow requirement: $2.5M due by year-end (Dec 31, 2025), which may strain liquidity for a micro-cap company.
- Aggressive royalty structure: 13% of net profit plus 90% of sublicensing revenue significantly limits the company's ability to retain earnings from this new venture.
- High minimum annual commitment: $1M/year starting in 2028 creates a significant fixed cost burden regardless of actual performance.
📋 Key Facts
- Entered into License Agreement with DataVault AI Inc. on November 24, 2025.
- Purpose: Development of 'PharmacyChain™', a blockchain-enabled smart contract technology for the prescription drug industry.
- Upfront Fee: $2,500,000 non-refundable license fee due by December 31, 2025.
- Royalty Fee: 13% on all net profit received from use of the license.
- Minimum Royalty: $1,000,000 annual minimum starting in calendar year 2028 (subject to a $2M net profit threshold for 2028 and 2029).
- Sublicensing Terms: Company must remit 90% of all net revenue from sublicenses to DataVault AI Inc.
Wellgistics Health, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025, via a press release.
📋 Key Facts
- The filing is a routine disclosure of quarterly financial results (Item 2.02).
- Financial results pertain to the quarter ended September 30, 2025.
- The company issued a press release as Exhibit 99.1 containing forward-looking statements.
- The filing was signed by Prashant Patel, President.
Wellgistics Health, Inc. announced the sudden resignation of its independent auditor, UHY LLP, effective November 11, 2025. The resignation is linked to uninvestigated information arising from the departure of the former CEO.
🚩 Red Flags
- Auditor resignation triggered by 'information' related to a former CEO departure (potential fraud/misconduct indicator).
- Uninvestigated issues regarding executive leadership.
- Existing material weaknesses in internal controls over financial reporting (control environment, risk assessment, and monitoring).
- Limited accounting personnel and supervisory resources noted in previous filings.
📋 Key Facts
- UHY LLP resigned as the Company's independent accountant on November 11, 2025.
- The resignation was prompted by 'certain information identified in the resignation of the former Chief Executive Officer' which remains uninvestigated.
- UHY had only been engaged since July 7, 2025, and did not audit any financial statements during their tenure.
- Suri & Co., Chartered Accountants has been re-engaged as the new independent auditor for the fiscal year ending December 31, 2025.
- The company previously disclosed material weaknesses in internal control over financial reporting in its June 30, 2025, 10-Q.
Wellgistics Health, Inc. announced multiple debt conversions and warrant exercises that resulted in the issuance of over 10 million new shares at a price of $0.70 per share. These actions significantly increase the company's total outstanding share count through equity dilution.
🚩 Red Flags
- Significant equity dilution via massive debt-to-equity conversions.
- Multiple related-party/subsidiary transactions involving WoodSage LLC (a wholly-owned subsidiary).
- The conversion price of $0.70 is notably low, suggesting potential downward pressure on share price.
📋 Key Facts
- On October 24, 2025, warrant holders exercised warrants for 3,111,429 shares at $0.70 per share.
- On October 30, 2025, the Company entered a Debt Conversion Agreement with Integra Health Inc. to convert $1,300,000 of debt into 1,857,143 common shares at $0.70 per share.
- On October 30, 2025, the Company entered a second Debt Conversion Agreement with Integra Pharma Solutions, LLC to convert $4,019,859 of debt into 5,742,656 common shares at $0.70 per share.
- Total new shares issued across all reported events: 10,711,228 shares.
Wellgistics Health, Inc. filed an 8-K to furnish a press release containing forward-looking statements regarding company projects and growth opportunities. The filing does not disclose specific material agreements or financial changes but serves as a vehicle for public communication under Regulation FD.
📋 Key Facts
- The filing was made on October 27, 2025.
- The company issued a press release (Exhibit 99.1) containing forward-looking statements regarding potential financial performance and growth opportunities.
- The registrant is an emerging growth company.
- The filing includes standard cautionary language regarding forward-looking statements under the Private Securities Litigation Reform Act of 1995.
Wellgistics Health, Inc. entered into a non-binding Letter of Intent (LOI) with DataVault to explore a collaboration involving 'PharmaChain,' a blockchain-enabled smart contract solution for the prescription drug industry.
🚩 Red Flags
- The LOI is non-binding and creates no legal obligation to consummate a transaction.
📋 Key Facts
- Entered into a non-binding LOI with DataVault on October 21, 2025.
- The proposed collaboration focuses on integrating PharmaChain technology into Wellgistics' infrastructure to digitize prescription fulfillment workflows.
- Potential revenue-sharing arrangement contemplated for future commercialization.
- The agreement explicitly states it does not involve the issuance of tokens or digital assets.
Wellgistics Health, Inc. filed an 8-K to furnish a press release issued on October 13, 2025, containing forward-looking statements regarding company projects and growth opportunities.
🚩 Red Flags
- None identified in this specific filing (the text provided is a placeholder for a press release rather than substantive financial data).
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- A press release was issued on October 13, 2025, which is attached as Exhibit 99.1.
- The company references a Form S-1 registration statement declared effective by the SEC on September 25, 2025.
Wellgistics Health, Inc. announced a sudden mass exodus of its top executive team, including the CEO, COO, and CFO, all effective October 6, 2025. The company has appointed Eric Sherb as interim CFO via an existing consulting agreement.
🚩 Red Flags
- Simultaneous departure of the entire C-suite (CEO, COO, CFO) is a major red flag indicating potential internal instability or impending material news.
- Suddenness of resignations (effective same day as announcement).
- Related-party transaction: The interim CFO is being paid through an entity he owns/controls via a pre-existing consulting agreement.
📋 Key Facts
- CEO Brian Norton resigned effective Oct 6, 2025, at 5:00 p.m. EST.
- COO Tony Madsen resigned effective Oct 6, 2025, at 8:00 p.m. EST.
- CFO Mark DiSiena resigned effective Oct 6, 2025, at 5:00 p.m. EST.
- Eric Sherb appointed as interim CFO effective Oct 7, 2025.
- Interim CFO Eric Sherb is being compensated via an existing consulting agreement with EMS Consulting Services, LLC (controlled by Mr. Sherb).
- Consulting rates for Mr. Sherb are $185/hour for CPA services and $80/hour for bookkeeping.
Wellgistics Health, Inc. underwent a massive board overhaul involving the removal of two directors by majority stockholder consent and the resignation of another director. Simultaneously, the company appointed four new directors and named Prashant Patel as President under a new three-year employment agreement.
🚩 Red Flags
- Massive board turnover: Removal of the Audit Committee Chair and an Ethics Committee member by majority stockholder consent is a significant governance event.
- Concentration of power/control change: The removal of directors via 'majority stockholder action' suggests a shift in control or a proxy battle outcome.
- Rapid leadership restructuring: Multiple changes to the board and executive team within a 72-hour window (Oct 1–Oct 3).
📋 Key Facts
- Majority stockholders removed Rebecca Shanahan (Ethics Committee) and Michael Peterson (Audit Committee Chair) effective Oct 1, 2025.
- Director Donald Anderson resigned effective Oct 2, 2025; stated no disagreement with management or the board.
- Four new directors elected: Donald Fell, Prashant Patel, Steven D. Lee, and Howard Doss.
- Prashant Patel appointed President effective Oct 3, 2025, with a $400,000 annual salary and a 3-year initial term.
- New non-employee directors receive a $120,000 cash retainer (or shares) plus 60,000 shares annually under the 2023 Equity Incentive Plan.
- Newly elected directors receive 200,000 restricted shares vesting over three years upon appointment.
Wellgistics Health, Inc. completed a $5 million public offering of common stock and warrants to fund working capital and R&D. The deal includes significant warrant coverage for both investors and the placement agent.
🚩 Red Flags
- Significant warrant overhang: Investors received 1:1 warrant coverage at the same price as the stock ($0.70), which is highly dilutive.
- Placement agent warrants (500,000 shares) create additional potential dilution.
- The company's use of proceeds for 'working capital and general corporate purposes' often indicates a need to cover immediate operational burn.
📋 Key Facts
- Offered 7,142,862 shares of common stock at $0.70 per share.
- Issued 7,142,862 warrants to purchase common stock at $0.70 per share (5-year term).
- Gross proceeds from the offering totaled approximately $5 million.
- H.C. Wainwright & Co., LLC acted as exclusive placement agent.
- Placement agent received a $350,000 cash fee and 500,000 warrants with an exercise price of $0.875.
- The offering was conducted via a previously declared S-1 registration statement.
Wellgistics Health, Inc. issued an 8-K to announce its participation in three upcoming business conferences in September 2025 and to provide updated corporate presentation materials.
📋 Key Facts
- Company will present at three business conferences during September 2025.
- Updated corporate presentation (Exhibit 99.2) and fact sheet (Exhibit 99.3) were released on September 8, 2025.
- The materials are intended for use with prospective investors and strategic partners.
Wellgistics Health, Inc. entered into a $1.3 million Business Loan and Security Agreement with Agile Capital Funding, LLC to fund working capital and refinance prior debt obligations.
🚩 Red Flags
- High cost of capital: The interest charge ($572k) on a $1.3M loan represents an extremely high effective APR, characteristic of distressed financing.
- Debt refinancing/layering: A portion of the proceeds was used to satisfy existing debt from May and June 2025, suggesting a cycle of high-interest borrowing to cover obligations.
- Aggressive repayment schedule: Weekly installments of $58,500 create significant immediate cash flow pressure.
📋 Key Facts
- Principal amount of the new loan: $1,300,000
- Maturity date: April 8, 2026
- Total interest charge: $572,000 (assuming timely payments)
- Repayment structure: Weekly installments of $58,500
- Net cash proceeds received: Approximately $500,000
- Purpose: General working capital and satisfying previously outstanding obligations from May and June 2025 agreements.
Wellgistics Health, Inc. filed an 8-K to announce the release of its financial results for the second fiscal quarter ended June 30, 2025.
📋 Key Facts
- The filing relates to the announcement of Q2 2025 financial results (period ended June 30, 2025).
- A press release containing the results was issued on August 20, 2025.
- The company is an emerging growth company.
Wellgistics Health, Inc. announced the immediate resignation of its President and board member, Prashant Patel, effective August 8, 2025. Additionally, the company terminated a significant $50 million equity line of credit (ELOC) previously entered into with Hudson Global Ventures, LLC.
🚩 Red Flags
- Immediate departure of a key executive (President).
- Termination of a $50M equity financing vehicle (ELOC), which may indicate the company no longer requires or is unable to utilize that specific funding source, or a shift in capital strategy.
- Multiple material events reported in a single 8-K filing (Officer departure + Termination of material agreement).
📋 Key Facts
- Prashant Patel resigned as President and board member effective August 8, 2025.
- The company terminated an Equity Line of Credit (ELOC) Purchase Agreement with Hudson Global Ventures, LLC on August 13, 2025.
- The ELOC had a potential capacity of up to $50,000,000 in common stock purchases.
- No termination fees or penalties were incurred from the cancellation of the ELOC.
- The company announced an 'XRP Implementation Program' via press release on August 13, 2025.
Wellgistics Health, Inc. has entered into an Eighth Amendment to its Membership Interest Purchase Agreement (MIPA), significantly altering the terms of payments owed to Sellers for a prior acquisition. The amendment involves converting cash obligations into equity and increasing the principal amount of existing promissory notes by $2.5 million.
🚩 Red Flags
- Related-party transaction: The amendment involves significant debt and equity restructuring with entities controlled by the CEO (Brian Norton).
- Debt escalation: The company increased its promissory note obligation from $15M to $17.5M, increasing future cash outflow requirements.
- Equity dilution: Conversion of ~$8.1M in cash into 7.6M shares will result in significant dilution for existing shareholders.
📋 Key Facts
- The remaining closing cash payment of $8,139,259.97 has been converted into 7,606,785 shares of common stock.
- Promissory notes payable to Sellers increased from $15 million to $17.5 million.
- Repayment schedule for the $17.5M principal: $5M due in one year, $5M due in two years, and $7.5M due in three years.
- The amendment involves Strategix Global LLC, which is controlled by Brian Norton, the Company's CEO.
- The company will pay $12,000 by July 31, 2025, to reimburse Sellers for fees related to various amendments.
Wellgistics Health, Inc. has dismissed its independent auditor, Suri & Co., and appointed UHY LLP as its new accounting firm effective July 7, 2025.
🚩 Red Flags
- Dismissal of auditor (Item 4.01) often warrants scrutiny in micro-cap companies.
- Previous audit reports for 2023 and 2024 contained going concern language, indicating significant doubt about the company's ability to continue operations.
📋 Key Facts
- Dismissal of Suri & Co., Chartered Accountants approved by the Board on July 7, 2025.
- Appointment of UHY LLP as the new independent registered public accounting firm, effective July 7, 2025.
- The previous auditor's reports for fiscal years ended Dec 31, 2024, and Dec 31, 2023, contained a 'going concern' note.
- The company stated there were no disagreements with the former auditor regarding accounting principles or auditing scope.
Wellgistics Health, Inc. has filed an 8-K to disclose a revised investor presentation posted on its website. The filing is made pursuant to Regulation FD disclosure requirements.
📋 Key Facts
- The company updated its investor presentation on wellgisticshealth.com on May 15, 2025.
- The presentation contains forward-looking statements regarding projects, potential financial performance, and growth opportunities.
- The filing is categorized under Item 7.01 (Regulation FD Disclosure).
Wellgistics Health, Inc. announced the appointment of Mark DiSiena as Chief Financial Officer, effective April 22, 2025, succeeding Vishnu Balu who is resigning without disagreement.
🚩 Red Flags
- Salary increase is contingent upon a significant $10 million funding round, suggesting the company is currently in need of capital.
- Equity compensation involves 150,000 restricted shares which may cause dilution to existing shareholders.
📋 Key Facts
- Mark DiSiena appointed CFO effective April 22, 2025.
- Vishnu Balu resigned from the CFO position; resignation was not due to any dispute or disagreement with the Company.
- DiSiena's base salary is $200,000 per year, increasing to $275,000 upon completion of a minimum $10 million funding round.
- The employment agreement includes 150,000 restricted shares of common stock vesting in equal annual installments starting December 31, 2025.
- DiSiena has an extensive background including roles at AgEagle Aerial Systems and consulting for companies like Paramount Pictures and American Apparel.
Wellgistics Health, Inc. amended its Membership Interest Purchase Agreement to convert a $1.5 million cash obligation owed to an entity controlled by the CEO into 333,333 shares of common stock.
🚩 Red Flags
- Related-party transaction: The cash debt is owed to Strategix Global, LLC, which is controlled by the Company's CEO, Brian Norton.
- Potential dilution: Conversion of $1.5M in debt into 333,333 shares represents a significant issuance of equity to an insider.
- Liquidity management: The conversion suggests the company may have preferred to preserve cash rather than settle the $1.5M obligation in currency.
📋 Key Facts
- Amendment to Wellgistics MIPA dated April 14, 2025.
- Conversion of $1,500,000 cash payment into 333,333 shares of common stock.
- The conversion price is based on the $4.50 IPO price.
- Shares to be issued by June 14, 2025.
- The Converted Shares are subject to a 12-month lock-up agreement for Strategix Global, LLC.
Wellgistics Health, Inc. has entered into a definitive merger agreement to acquire Peek Healthcare Technologies, Inc., which includes significant cash and debt considerations. Additionally, the company issued a $500,000 promissory note to a related party and established a $50 million equity line of credit (ELOC).
🚩 Red Flags
- Related-party transaction: $500,000 note issued to Sansur Associates, LLC, which is beneficially owned by the Company's Chairman, Suren Ajjarapu.
- High dilution risk: The $50 million ELOC allows for significant issuance of common stock at a 10% discount to market price.
- Significant debt load increase: The merger includes an immediate $6,000,000 unsecured promissory note obligation.
- Short-term liquidity pressure: The related-party note matures in less than six months (October 2025).
📋 Key Facts
- Entered into an Agreement and Plan of Merger with Peek Healthcare Technologies, Inc. on April 8, 2025.
- Merger consideration includes $2,000,000 cash (subject to adjustments) and a $6,000,000 unsecured promissory note at 4.5% interest maturing in three years.
- Peek stockholders to receive up to 1,777,778 shares of WGRX common stock, including an earn-out component based on achieving $8.8M in revenue by Dec 31, 2027.
- Issued a $500,000 unsecured promissory note on April 7, 2025, to Sansur Associates, LLC (a related party) at 10% interest maturing Oct 4, 2025.
- Entered into an Equity Line of Credit (ELOC) with Hudson Global Ventures, LLC for up to $50,000,000 in common stock over 24 months.
- The ELOC purchase price is a discount of 10% to the current market price.
Wellgistics Health, Inc. granted a massive aggregate of 19,764,108 shares of restricted stock to various directors, employees, and consultants under its 2023 Equity Incentive Plan. The issuance includes significant immediate vesting for non-independent directors and large performance-based grants for the CEO.
🚩 Red Flags
- Significant dilution risk: The issuance of nearly 20 million shares represents a massive expansion of the share count.
- Immediate vesting for non-independent directors (8.16M shares) creates immediate downward pressure upon sale and lacks long-term alignment incentives.
- Large performance-based grant to CEO (9M shares) can lead to aggressive accounting or management behavior to hit specific metrics.
📋 Key Facts
- Total shares granted: 19,764,108 restricted stock units.
- Non-independent directors received 8,164,494 shares with immediate vesting.
- CEO Brian Norton was granted 9,000,000 shares subject to performance metrics for fiscal years 2025, 2026, and 2027.
- Independent directors received 600,000 shares (198,000 vesting immediately; remainder over two years).
- Issuance relied on Section 4(a)(2) exemption from registration under the Securities Act of 1933.
Wellgistics Health, Inc. entered into a consulting agreement with Draper, Inc. for investor relations and business development services. The compensation structure involves significant equity issuance to the consultant.
🚩 Red Flags
- Significant equity dilution: The agreement grants 100,000 shares upfront and potentially 100,000 additional shares every month for ongoing services.
- Potential conflict of interest/Related party risk: The consultant is tasked with 'assisting the Company in financing arrangement to be determined', which can create misaligned incentives regarding share issuance.
📋 Key Facts
- Entered into a Consulting Agreement with Draper, Inc. on March 17, 2025.
- Services include IR, business development, financial requirement analysis, and assisting in financing arrangements.
- Initial term is three months with automatic one-month renewals.
- Compensation: 100,000 restricted shares of common stock upon execution; an additional 100,000 shares for each subsequent monthly renewal term.
- Company achieved SOC 2 Type 1 compliance as announced via press release on March 18, 2025.
Wellgistics Health, Inc. announced the promotion of Brian Norton to CEO, succeeding Timothy Canning. The filing details significant related-party transactions involving Mr. Norton and his previous entity, Wellgistics LLC, including substantial cash payments, promissory notes, and equity issuances.
🚩 Red Flags
- Extensive related-party transactions: The CEO was a principal in the entity (Wellgistics LLC) being acquired by the Company.
- Significant debt/liabilities: A $15 million promissory note is owed to parties involved in the MIPA.
- Complex equity structures: Large RSU grants and previous share issuances linked to the acquisition of an insider-controlled entity.
- Potential liquidity pressure: The company has a $10 million cash obligation due by August 30, 2025.
📋 Key Facts
- Brian Norton promoted to CEO effective February 28, 2025; succeeds Timothy Canning.
- Norton's new compensation includes a $490,000 base salary and up to 100% performance bonus.
- Grant of 9,000,000 RSUs to Norton vesting over three years based on revenue/profit targets.
- The Company is subject to a $15 million promissory note (plus interest) related to the acquisition of Wellgistics LLC.
- A $10 million cash payment due by August 30, 2025, was recently extended via amendment to the MIPA.
- Significant equity issuances occurred in November 2024 involving over 3.9 million shares related to the acquisition of Wellgistics LLC.
Wellgistics Health, Inc. entered into a 30-day consulting agreement with Hudson Global Ventures, LLC for business advisory and growth strategy services. The compensation includes a $250,000 cash fee and the issuance of 52,000 shares of common stock.
🚩 Red Flags
- Short-term consulting agreement (30 days) with high cash/equity compensation may suggest urgent need for advisory or rapid capital deployment.
- The inclusion of registration rights for the consultant's shares is a common feature in micro-cap financing that can lead to future dilution.
📋 Key Facts
- Consulting Agreement entered into on February 25, 2025, with Hudson Global Ventures, LLC.
- Term of agreement is thirty (30) days.
- Compensation includes a $250,000 cash fee.
- Compensation includes the issuance of 52,000 shares of common stock ($0.0001 par value).
- Hudson Global Ventures has registration rights for its shares in any future SEC filings by the Company.
Wellgistics Health, Inc. (WGRX) has completed an initial public offering (IPO) of 888,889 shares at $4.50 per share. The offering generated approximately $3.1 million in net proceeds to increase capitalization and provide working capital.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of new common stock.
📋 Key Facts
- Offered 888,889 shares of common stock at a price of $4.50 per share.
- Gross proceeds from the offering totaled $4,000,000.
- Net proceeds to the company are approximately $3.1 million after expenses and commissions.
- The offering was underwritten by Craft Capital Management LLC.
- Trading commenced on Nasdaq Capital Market LLC under ticker 'WGRX' on February 21, 2025.
- Registration Statement (Form S-1) was declared effective by the SEC on February 14, 2025.